- CEO
- Hiromasa Kunimitsu
- Full Time Employees
- 858
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Shin-Osaka Brick Building Osaka OS Japan 532-0003
- IPO Date
- Dec 15, 2000
- Business
- EM Systems Co., Ltd. develops, sells, and maintains specialized IT systems for pharmacies, clinics, and long-term care/welfare providers in Japan. The company offers pharmacy systems including medical fee receipt computers, electronic medication record systems such as MAPs for PHARMACY, MAPs for PHARMACY DX, Recepty NEXT, and Bungyo-Mate; medical systems for clinics and hospitals encompassing medical accounting software and electronic medical records like MAPs for CLINIC, MRN, Ortia, and UNI-MEDICAL; nursing care and welfare systems such as HIBIKI-SYMPHONY, SUKOYAKA-san, and MAPs for NURSING CARE; as well as other services including cloud-based subscription models, application service provider Internet dispensing support, statistical information analysis, cashless payments via subsidiary ChoQi Co., Ltd., and pharmacy operations through Brick Pharmacy Inc. EM Systems operates 33 sales offices nationwide, holds leading market shares of 43.9% in pharmacy IT systems, 3.6% in clinic systems, and 4.9% in nursing care systems as of December 2024, and maintains a network integrating healthcare data across providers. Founded in 1980 and headquartered at 6-1 Miyahara 1-chome, Yodogawa-ku, Osaka, the company lists on the Tokyo Stock Exchange Prime section (4820) and oversees subsidiaries including EM Technology Laboratory Co., Ltd., Good Cycle System Inc., precal, Inc., Pop-Creation Co., Ltd., UNIKE SOFTWARE RESEARCH CO., LTD., Brick Pharmacy Inc., EM TOWN Co., Ltd., Lasante Co., Ltd., Meisho System Co., Ltd., and overseas entities EM Software Systems Development (N.J.) Co., Ltd. and EM Software Systems Development (S.H.) Co., Ltd. Recent developments include treasury stock acquisitions from February 2024 totaling 1,600,000 shares for ¥1,000 million to support flexible capital policy, upgrades to FY2025 Q1-Q2 forecasts amid progress in medical DX initiatives like online eligibility verification and electronic prescription systems, and a new mid-term management plan for FY2025-FY2027 emphasizing growth investments, M&A, and shareholder returns with targeted free cash flow of ¥7,500 million.